Dr. Asrani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1470 Madison Avenue
Tisch Cancer Institute
New York, NY 10029Phone+1 212-824-7318
Summary
- Roshan Asrani, MD, is a hematology/oncology specialist based in New York, NY, with a focus on Lymphoma. He completed his fellowship in Hematology and Medical Oncology at Stony Brook Medicine, where he also served as Chief Fellow. His education also includes a residency in Internal Medicine at Albany Medical Center and a degree in Biomedical Engineering from Cornell University. Dr. Asrani is an Assistant Professor at the Icahn School of Medicine at Mount Sinai where he sees clinic patients, oversees clinical trials as a principal and sub-investigator and has a prominent role in the selection and training of oncology trainees. Dr. Asrani also serves as the wellness chair for the hematology/oncology fellowship program and serves on the wellness committee for the Ruttenberg Treatment Center and Tisch Cancer Institute. He is skilled in procedures such as lumbar puncture with intrathecal chemotherapy administration and bone marrow aspiration and has contributed to research with publications on rare lymphomas and COVID coagulopathy.
Education & Training
- Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2019 - 2022
- Stony Brook MedicineFellowship, Hematology/Oncology, Chief Fellow, 2019 - 2022
- Albany Medical CenterResidency, Internal Medicine, 2016 - 2019
- Ross University School of MedicineClass of 2016
- Cornell UniversityBS, Biomedical Engineering, 2008 - 2012
- Clarkson UniversityBS, Chemical engineeeing, Presidential Scholar, 2007 - 2008
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- NY State Medical License 2019 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- American Heart AssociationACLS
- American Heart AssociationBLS
Clinical Trials
- Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma Start of enrollment: 2024 Jun 01
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Start of enrollment: 2024 Jun 24
- Join now to see all
Publications & Presentations
PubMed
- Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.Roshan Asrani, Turgot Bora Cengiz, Bruce E Petersen, Theodora Anagnostou, Joshua D Brody
Frontiers in Oncology. 2023-01-01 - 2 citationsAcute Myeloid Leukemia with Philadelphia Chromosome, Near-tetraploidy, and 5q Deletion.Abdul Moiz Khan, Ayesha Munir, Roshan Asrani, Saleh Najjar
Cureus. 2019-09-09
Journal Articles
- COVID Coagulopathy and Thrombosis: A systematic reviewAsrani R, Bahou WF., touchREVIEWS in Oncology & Haematology, 2/28/2022
Committees
- Wellness Chair, Hematology/Oncology Fellowship 2024 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: